Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...
MedPage Today on MSN20h
Endocrine Society Condemns HHS Purge; Lilly Sues Compounders; Obesity Rising in T1DCombination treatment with a GLP-1 agonist and thiazolidinedione in type 2 diabetes was tied to a significantly lower risk of ...
Lilly continues full-court press against breast cancer with women's March Madness event sponsorships
As the women’s NCAA March Madness tournament draws to a close, Eli Lilly is aiming for a slam dunk of its own. | As the women ...
Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.
Tobacco giant Altria (NYSE: MO) provides a tremendously high dividend yield of 7%, which is well above the S&P 500 index ...
Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback